CatalystFDA/Bio

CELLDEX THERAPEUTICS, INC. (CLDX) DISCUSSES POSITIVE PHASE 3 RESULTS FOR BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIA TRANSCRIPT - SEEKINGALPHA

Positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria drive high relevance.

What changed

Positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria drive high relevance.

Why it matters

Positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria drive high relevance. — impact context not separately stored; see What changed.

Sources

seekingalpha